Consumers and health professionals are advised that a further product has been affected by the below issue.
Certain batches of methotrexate 2.5 mg tablets in bottles of 30, marketed as DBL Methotrexate Tablets, are being recalled.
Further information regarding this recall action, including what you should do if you or someone you care for takes this medicine, is available in the full safety alert.
Please note that this recall action differs slightly from the previous recall of a methotrexate product, marketed as Methoblastin, listed below. While the previous recall for product correction instructed consumers to take the bottles to their pharmacy to receive a replacement cap, this product is subject to a full recall as replacement caps are not currently available.
Return affected products to your pharmacy
12 March 2015
Some medicines can be toxic to children and are required to be supplied in child-resistant packaging. When these medicines are supplied in bottles, they must have a child-resistant closure (cap).
Consumers and health professionals are advised that a number of different medicines are subject to recall actions because they have been supplied to the market in bottles without child-resistant caps (see below for links to alerts for those medicines).
Some of the products affected by these recall actions are essential medicines that cannot be suddenly ceased or substituted. As there are no replacement medicines available, a full recall would disrupt treatment for those patients. Therefore those medicines should be taken to a pharmacy so that the caps and/or bottles can be replaced with child-resistant versions.
The other products, for which replacement or alternative treatments are available, are subject to a full recall.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.